Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Base...( ROCKVILLE Md. and NANTES France Feb. ...)

ROCKVILLE, Md. and NANTES, France, Feb. 4 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX) and Vivalis (NYSE Euronext: VLS) announced today the completion of a research license to use the Vivalis proprietary EB66(R) cell line, for the production of Novavax VLP based vaccines. Through this collaboration, Novavax intends to test the EB66(R) cell line for the production of VLP vaccines against several new potential viruses.

The EB66(R) cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics: (i) EB66(R) cells display long term genetic stability and immortality; (ii) they grow in suspension up to high cell densities in serum free medium; (iii) they can be scaled up for growth in large bioreactors for industrial productions; (iv) a biological master file (BMF) describing the history and sanitary status of the cell line is filed with the US Food and Drug Administration (FDA).

"Novavax is delighted to have the opportunity to evaluate the EB66(R) cell line for its potential use with our new VLP targets" stated Rahul Singhvi, Chief Executive Officer of Novavax. "This collaboration is consistent with our manufacturing strategy to use scalable cell culture solutions for production of recombinant VLP vaccines and increases our flexibility to design, develop and manufacture such vaccines to address significant unmet medical needs."

"Vivalis is very pleased to enter into this research license agreement with Novavax, one of the leading companies in the development of VLP based vaccines. Following the demonstration that the EB66(R) cell line is a promising substrate for the production of numerous viral vaccines such as flu or MVA based vaccines but also for the production of enhanced ADCC monoclonal antibody, we are delighted to start this program with Novavax to evaluate the us
'/>"/>